We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ADXS market cap is 4.48M. The company's latest EPS is USD -1.1276 and P/E is -0.10.
| Year End December 30 2023 | 2020 | 2021 | 2022 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 253k | 3.24M | 250k | 0 | 13k |
| Operating Income | -26.45M | -18.79M | -19.31M | 0 | -36.27M |
| Net Income | -26.47M | -17.86M | -15.38M | 0 | -48.07M |
| Year End December 30 2023 | 2020 | 2021 | 2022 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 38.53M | 46.78M | 25.93M | 7.77M | 16.58M |
| Total Liabilities | 8.35M | 7.89M | 2.3M | 8.87M | 41M |
| Total Equity | 30.18M | 38.89M | 23.63M | -1.1M | -24.42M |
| Year End December 30 2023 | 2020 | 2021 | 2022 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -21.94M | -15.44M | -15.28M | N/A | -29.49M |
| Investing | -748k | -11k | -166k | N/A | 5.95M |
| Financing | 15.5M | 31.89M | -956k | N/A | 26M |
| Market Cap | 4.48M |
| Price to Earnings Ratio | -0.10 |
| Price to Sales Ratio | 366.67 |
| Price to Cash Ratio | 0.96 |
| Price to Book Ratio | -0.19 |
| Dividend Yield | - |
| Shares Outstanding | 42.63M |
| Average Volume (1 week) | 7.14k |
| Average Volume (1 Month) | 2.68k |
| 52 Week Change | -86.86% |
| 52 Week High | 1.49 |
| 52 Week Low | 0.0012 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Ayala Pharmaceuticals Inc (CE) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.ayalapharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
